These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 25966349

  • 1. Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies.
    Culshaw GJ, MacIntyre IM, Dhaun N, Webb DJ.
    Semin Nephrol; 2015 Mar; 35(2):176-87. PubMed ID: 25966349
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Endothelin antagonism in patients with nondiabetic chronic kidney disease.
    Dhaun N, Goddard J, Webb DJ.
    Contrib Nephrol; 2011 Mar; 172():243-254. PubMed ID: 21894004
    [Abstract] [Full Text] [Related]

  • 5. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.
    Benigni A, Buelli S, Kohan DE.
    Pediatr Nephrol; 2021 Apr; 36(4):763-775. PubMed ID: 32185491
    [Abstract] [Full Text] [Related]

  • 6. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W, Pittrow D.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [Abstract] [Full Text] [Related]

  • 7. Endothelin Receptor Antagonists: New Hope for Renal Protection?
    Tobe S, Kohan DE, Singarayer R.
    Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
    [Abstract] [Full Text] [Related]

  • 8. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future?
    Vaněčková I, Hojná S, Kadlecová M, Vernerová Z, Kopkan L, Červenka L, Zicha J.
    Physiol Res; 2018 Jun 27; 67(Suppl 1):S55-S67. PubMed ID: 29947528
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic potential of endothelin receptor antagonism in kidney disease.
    Czopek A, Moorhouse R, Webb DJ, Dhaun N.
    Am J Physiol Regul Integr Comp Physiol; 2016 Mar 01; 310(5):R388-97. PubMed ID: 26702154
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Endothelin and tubulointerstitial renal disease.
    Ong AC, von Websky K, Hocher B.
    Semin Nephrol; 2015 Mar 01; 35(2):197-207. PubMed ID: 25966351
    [Abstract] [Full Text] [Related]

  • 13. Endothelin: a mediator of renal disease progression.
    Bruzzi I, Remuzzi G, Benigni A.
    J Nephrol; 1997 Mar 01; 10(4):179-83. PubMed ID: 9377723
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Endothelin antagonism and hypertension: an evolving target.
    Laffin LJ, Bakris GL.
    Semin Nephrol; 2015 Mar 01; 35(2):168-75. PubMed ID: 25966348
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.